Aim: A recent study found that the Optineurin (OPTN) gene was mutated in families with primary open angle glaucoma (POAG), A misense mutation E50K was present in 13.5% of families studied, and the M98K risk-associated...Aim: A recent study found that the Optineurin (OPTN) gene was mutated in families with primary open angle glaucoma (POAG), A misense mutation E50K was present in 13.5% of families studied, and the M98K risk-associated change was identified in 13.6% of POAG subjects. The aim of this study was to investi-展开更多
Aim: To compare the effect of brimonidine and timolol in reducing visual field loss in acute primary angle closure (APAC) patients. Methods: In addition to standard medical treatment, A-PAC patients were randomised to...Aim: To compare the effect of brimonidine and timolol in reducing visual field loss in acute primary angle closure (APAC) patients. Methods: In addition to standard medical treatment, A-PAC patients were randomised to brimonidine 0.2% or timolol 0.5% at presentation, then twice daily for one month. After laser iridotomy, subjects underwent baseline perimetry during the展开更多
文摘Aim: A recent study found that the Optineurin (OPTN) gene was mutated in families with primary open angle glaucoma (POAG), A misense mutation E50K was present in 13.5% of families studied, and the M98K risk-associated change was identified in 13.6% of POAG subjects. The aim of this study was to investi-
文摘Aim: To compare the effect of brimonidine and timolol in reducing visual field loss in acute primary angle closure (APAC) patients. Methods: In addition to standard medical treatment, A-PAC patients were randomised to brimonidine 0.2% or timolol 0.5% at presentation, then twice daily for one month. After laser iridotomy, subjects underwent baseline perimetry during the
